# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humir...
The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually. Data to be...
Cantor Fitzgerald analyst Louise Chen initiates coverage on AbbVie (NYSE:ABBV) with a Overweight rating and announces Price ...
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop nex...